PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Concept Life Sciences appoints industry veteran Dean Bornilla as Chief Commercial Officer to drive international expansion


Concept Life Sciences, a leading contract research organisation (CRO) specialising in drug discovery and development, materials science, and safety toxicology, has appointed Dean Bornilla as Chief Commercial Officer (CCO) to spearhead its international growth strategy, with a focus on expanding its presence in North America and Europe.

The appointment brings more than 25 years of life sciences commercial leadership experience to Concept as the company looks to strengthen its position in key global markets, deepen strategic customer relationships and broaden access to its specialist scientific capabilities.

Bornilla joins the company following senior commercial leadership roles at Pace Life Sciences, Selvita and Curia (formerly AMRI), where he led commercial growth initiatives, international market expansion and strategic customer development across the CRO, CDMO and pharmaceutical sectors.

As Chief Commercial Officer, Bornilla will lead the company’s global commercial operations, including sales, business development, marketing and strategic account management. A key priority will be connecting pharmaceutical, biotechnology and wider scientific organisations with Concept’s integrated scientific services, helping customers address increasingly complex research and development challenges.

Dr. Adrijana Vinter, Chief Executive Officer of Concept Life Sciences, commented: “Dean Bornilla joins us at an important stage in our growth strategy. With considerable experience across the  scientific services sector, he brings the commercial expertise, international perspective and customer focus needed to help us realise our ambitions.

“Our scientific capabilities provide a strong foundation for growth, and this appointment is about building on that strength. He will play a key role in expanding our reach in priority markets, developing deeper customer partnerships and ensuring more organisations can benefit from the breadth of expertise we offer.”

Dean Bornilla, Chief Commercial Officer of Concept Life Sciences, commented:
“Concept Life Sciences has an impressive breadth of scientific expertise and a strong reputation for helping customers solve complex challenges. What attracted me to the business is the opportunity to build on those strengths and bring its capabilities to a wider international customer base. Our differentiated capabilities across drug discovery and development, material sciences, and safety toxicology position us to address a broad range of increasingly complex scientific challenges.

“My priority will be to strengthen our commercial organisation, deepen relationships with existing customers and open new opportunities in North America, Europe and other strategic markets. By connecting customers with the right expertise across our portfolio, we can support their innovation goals while delivering sustainable growth for the business.”




About Concept Life Sciences

Concept Life Sciences is a leading contract research organisation (CRO) serving the global life science and broader scientific industries. For over 25 years, the company and its heritage companies, have provided consultative and collaborative services across drug discovery and development, safety toxicity and materials science. Our approach, supported by passionate scientists and world-leading capabilities, enables clients to overcome complex scientific challenges and improves program success rates. The company has successfully helped 29 candidates advance to the clinic.

The company offers sophisticated translational biology services coupled with exceptional end-to-end chemistry capabilities, with the ability to seamlessly integrate capabilities and provide bespoke solutions to address client needs.

Collectively, the company’s high-quality services and commitment to customer service across the drug development pathway enhance efficiency in drug discovery, helping clients advance their drugs to clinic in as little as 32 months, well ahead of the industry average of 60 months.

The company operates from state-of-the-art UK facilities, headquartered near Manchester, with additional operations in Edinburgh, Dundee and Sandwich. The headquarters is one of the UK’s largest medicinal chemistry CRO sites with key discovery services all under one roof.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026